Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8

RADIATION4 trials

Sponsors

Fred Hutchinson Cancer Center

Conditions

Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaChronic Myelomonocytic LeukemiaCutaneous B-cell Non-Hodgkin LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHepatosplenic T-cell LymphomaIntraocular Lymphoma

Phase 1

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

CompletedNCT01300572

Fred Hutchinson Cancer CenterChronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia +3

Start: 2012-01-31End: 2019-11-22Updated: 2019-12-10

90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

CompletedNCT01503242

Fred Hutchinson Cancer CenterPlasma Cell Myeloma, Refractory Plasma Cell Myeloma

Start: 2012-01-09End: 2019-12-06Updated: 2019-12-09

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

TerminatedNCT01678443

Fred Hutchinson Cancer CenterAdult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma +30

Start: 1999-09-01End: 2018-09-27Updated: 2021-04-02

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

CompletedNCT01921387

Fred Hutchinson Cancer CenterRecurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma +5

Start: 2013-10-09End: 2020-07-26Updated: 2020-08-04

Related Papers

Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia

Haematologica2019-10-0329 citations

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody (90Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

Blood2018-11-298 citations

Safety and Efficacy of Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Followed by Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Chemotherapy and Autologous Stem Cell Transplantation (ASCT) for High-Risk Lymphoma

Biology of Blood and Marrow Transplantation2018-02-036 citations